Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study

Arantza Fariña-Sarasqueta, Gesina Lijnschoten, Harm J. T. Rutten, Adriaan J. C. van den Brule

► To cite this version:

Arantza Fariña-Sarasqueta, Gesina Lijnschoten, Harm J. T. Rutten, Adriaan J. C. van den Brule. Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study. *Cancer Chemotherapy and Pharmacology*, 2010, 66 (6), pp.1167-1171. 10.1007/s00280-010-1403-0 . hal-00612022

HAL Id: hal-00612022

<https://hal.science/hal-00612022>

Submitted on 28 Jul 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study

Arantza Fariña-Sarasqueta^{1,2}, Gesina van Lijnschoten¹, Harm, J.T. Rutten³, Adriaan J.C. van den Brule¹

¹ Department of Molecular Diagnostics, PAMM laboratory of pathology, Michelangelolaan 2, 5029 EJ Eindhoven, the Netherlands

² Department of Applied Sciences, Fontys University of Applied Science, Rachelsmolen 1, 5612 MA Eindhoven, the Netherlands

³ Department of surgery, Catharina hospital Eindhoven, Michelangelolaan 2, 5029 EJ, Eindhoven, the Netherlands

Disclosures: None

Corresponding author

A.J.C. van den Brule, PhD

Department of Molecular Diagnostics

PAMM laboratory of pathology

Michelangelolaan 2

5029 EJ Eindhoven

The Netherlands

Phone: +31 (0)40-239 61 00

Fax: +31 (0)40- 239 61 09

Email: a.van.den.brule@pamm.nl

Abstract

Purpose: The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in stage III colon carcinoma patients.

Methods: DNA was isolated from normal colonic tissue of 60 stage III colon carcinoma patients treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real time PCR, sequencing and RFLP were used for genotyping..

Results: None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival.

Conclusion: In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group.

Keywords: 5-FU, colon carcinoma, OPRT, DPYD, TYMS, TYMP, SNP

1 **Introduction**

2 In colon cancer, the role of pharmacogenetics for drug toxicity and efficacy is still under discussion [1].

3 5-Fluorouracil (5-FU) is the main drug of choice in the treatment of stage III colon carcinoma. Several
4 proteins are involved in the metabolism of 5-FU and many of the genes coding for these proteins have been
5 shown to be polymorphic.

6 Orotate phosphorybosil transferase (OPRT) and thymidine phosphorylase (TP) activate 5-FU by
7 phosphorylation into active metabolites which respectively incorporate into RNA or inhibit thymidylate
8 synthase (TS). Dihydropyrimidine dehydrogenase (DPD) inactivates 5-FU in the liver [2, 3]. The genes
9 encoding for these proteins harbor functional polymorphisms.

10 The OPRT gene contains several polymorphisms, among those the G638C SNP causes a Gly²¹³Ala
11 substitution. This SNP has been associated with a higher expression and activity of the protein and with an
12 increased toxicity of 5-FU therapy [4].

13 There are several polymorphisms described in the TP gene (TYMP), however there are no confirmed
14 polymorphisms in coding regions causing changes in aminoacid sequence. The value of these
15 polymorphisms as markers of response to 5-FU therapy is to our knowledge, unknown.

16 The polymorphisms in the enhancer region of the TS gene (TYMS) have been widely studied in their
17 relation to response to 5-FU therapy and with protein expression and activity. The studied polymorphisms
18 consist in a 28bp repeat at the 5' untranslated region of the gene and a G>C SNP in the second repeat of the
19 three repeat allele. In the Caucasian population the variants with two (2R) or three (3R) repeats are the most
20 frequent alleles found. On the basis of the effects of the SNP in the second repeat of the 3R allele on TS
21 protein expression, patients could be classified as high TS protein producers when carrying the G allele and
22 low TS protein producers when carrying the C allele [5, 6]. However, up to date, the results concerning the
23 effect of these polymorphisms in 5-FU response remain inconclusive [7].

24 Finally, the DPYD gene has been shown to play a very important role in toxicity of 5-FU. The
25 polymorphism in the exon/intron boundary at exon 14 is responsible for severe toxicity in these patients
26 [8]. However, little is known about the value of these and other polymorphisms as markers of response.

27 We aimed to study the value of known polymorphisms in the OPRT, TYMP, TYMS and DPYD genes as
28 markers of response in stage III colon carcinoma patients treated with 5-FU chemotherapy in combination

1 with leucovorin.

2

3

1 **Materials and methods**

2 *Patient material*

3 Sixty stage III colon carcinoma patients treated with surgery and 5-FU chemotherapy following the Mayo
4 regime were studied.

5 All diagnoses were made at a central laboratory for pathology between 2003 and 2004. Population data
6 were obtained from the cancer registry database of the Comprehensive Cancer Centre South. Follow-up
7 information was obtained from medical records.

8 The use of clinical material for this retrospective study was approved by the institutional review board
9 according to the guidelines of the Dutch Federation of Research Associations.

10 DNA was isolated from normal colonic mucosa from formalin fixed paraffin embedded (FFPE) material
11 after proteinase K digestion and purification using the HPTTP kit (Roche, Almere, the Netherlands).

12 *Target genes and polymorphisms*

13 Polymorphisms must be non synonymous and confirmed by independent research groups. However, in the
14 case of the TYMP gene, there were no confirmed non synonymous polymorphisms and therefore we chose
15 one confirmed synonymous polymorphism.

16 *OPRT*

17 The G638C SNP (rs1801019) causing a Gly213Ala substitution was tested by real time PCR with the
18 following primers and probes forward 5' GCT GAG ACA GTT GGG AGA GTG A 3', reverse 5' TGA
19 GTT CTT TGG GTG CTT CCT T 3', probe for G allele 6FAM 5'CGA ATC ATA ATG GTT C3'and
20 probe for C allele 6FAM 5'AGC GAA TCA TAA TGC TT3'. Reactions were performed using Roche
21 chemistry in a final volume of 20 µl in the light cycler v2 (Roche, Almere, the Netherlands).

22 *TYMP*

23 The rs470119 SNP was assessed by restriction fragment length polymorphism (RFLP). PCR was performed
24 using the following primers forward 6FAM-5'TCC AGA GCC CAG GTA3' and reverse 5'CTG GCC
25 AGG GTC TCC ATC A3'. The 71 bp long PCR product was then digested with MboI restriction enzyme
26 (New England Biolabs, Ipswich, United Kingdom). After digestion, fragment length analysis was carried
27 out by capillary electrophoresis. The following fragment length was expected for homozygous GG, 40bp
28 and 30bp, for AA 71 bp and for heterozygous AG 71bp, 40bp and 30bp.

1 *TYMS*

2 The two polymorphisms in the enhancer region of this gene were typed using PCR and RFLP as described
3 elsewhere [9]. Briefly, the 28 bp repeat was typed by PCR means followed by electrophoresis on 2%
4 agarose gel. The G>C SNP was typed by digestion of the PCR product with HaeIII restriction enzyme. The
5 G to C substitution abrogates the restriction site for this enzyme. Subsequently, products were separated by
6 agarose gel electrophoresis.

7 *DYPD*

8 The SNP A1627G (rs1801159) causing Ile543Val was tested by PCR followed by sequencing using the
9 following primers, forward 5'GCA GTC ACA ATA TGG AGC3' and reverse 5'TTA CCT TAT CAA
10 GAG AGA AAG TT3'. The expected length of the product was 225 bp. Subsequently, PCR products were
11 purified using enzymatic purification with ExoSapIT (USB, USA) and the sequencing reaction was
12 performed using the same primers as for the PCR reaction and Big Dye chemistry (Applied Biosystems,
13 Nieuwerkerk aan den IJssel, the Netherlands). Sequences were analyzed using the sequencing analysis 5.3.3
14 software (Applied Biosystems)

15 *Statistical Analysis*

16 SPSS software package for Windows (Chicago, Il., U.S.A.) was used for statistical analysis.
17 Categorical data were analyzed by means of a chi-square or Fischer's exact test. The end point of
18 this study was progression free survival (PFS, time between surgery and disease progression).

19 Univariate survival analysis was performed by Kaplan Meier analysis and differences were analyzed using
20 the Log Rank method. Hazard Ratios and multivariate analysis were calculated using the Cox Proportional
21 Hazard model.

22 All tests are two tailed and a result was considered significant when $p=0.05$.

23

Results

Briefly, characteristics of the sixty patients studied were as follows, median age at diagnosis was 64 years (range 30-81), fifty two percent (n=31) of the tumors were located on the right side of the colon and 53% (n=32) of the patients were male. The majority 70% (n=42) had a T3 tumor. Median follow up was 39 months (range 2-57). 40% was still alive without evidence of disease at the end of the follow up, 24% had developed a local recidive or a distant metastasis, 31% was dead because of cancer related causes and 5.2% was dead because of non cancer related causes as specified in their medical records. Median time to progression was 15 months (range 6-47)

Frequencies of the different alleles are shown in table 1. All frequencies followed Hardy-Weinberg equilibrium and did not differ significantly from frequencies published on the hapmap database for the Caucasian population.

In this group of patients, there were no significant associations between any of the genotypes found and any of the clinical and histopathological variables tested including gender, tumor location, T stage and N stage.

Survival Analysis

For the survival analysis, TYMS SNP genotypes were grouped as putative high TS expression (genotypes 2R/3G, 3C/3G and 3G/3G) and putative low TS expression (2R/2R, 2R/3C, 3C/3C). No effect on progression free survival of the several genotypes found was seen in a univariate (figure 1) or in a multivariate survival analysis, containing other known prognostic variables for colon carcinoma such as T stage and N stage of the tumor.

Discussion

We aimed to study whether known SNPs in genes involved in 5-FU metabolism were good markers of therapy response in stage III colon carcinoma patients.

According to our results, we conclude that the SNPs tested in the OPRT, TYMP, TYMS and DPYD genes are not good markers of therapy response in the present cohort. No effect on survival of the different genotypes was seen, however, results should be considered with caution due to the small number of patients analyzed.

Although, increased expression of OPRT mRNA and protein activity have been related to a shorter survival of colorectal carcinoma patients treated with 5-FU [10-12] together with the fact that the studied SNP has been proven to be associated to a higher protein expression and activity [13] [4], no effects of the different genotypes in DFS was seen in the present cohort. The OPRT CC variant is very rare in the general population. Our results reflect the low frequency of this genotype in the Caucasian population. If the CC variant would have an effect on survival, the fact that it is such a rare variant makes it very difficult to prove since numbers of patients needed would be very large.

The existing literature is more conclusive about TP protein expression which seems to have no influence in survival of colorectal patients [14-19]. Accordingly, the SNP in the TYMP gene was not a good marker for therapy response in our group.

The role of the typed polymorphisms on the TYMS gene remains controversial. It has been widely studied as protein and mRNA expression as well as DNA genotyping, still the results are inconclusive as reviewed by Popat *et al* [7]. These contradictory results are probably due to differences in methodology, technology and patients' selection. In the present patient group, TYMS polymorphisms in the enhancer region are not good markers of therapy response, even when grouping patient by category of putative TS expression no difference in survival was found between putative low and high producers. These results agree with previous results in a larger cohort of patients [20].

Finally, although DPYD has been widely studied in relation to 5-FU toxicity, it also seems to have a role in outcome [15, 19, 21-23]. However, whether this effect is due to the enzyme itself or due to high toxicity and subsequent therapy interruption is not clear. In the present cohort of patients, the studied SNP is not a good marker of therapy response.

In conclusion, polymorphisms in genes involved in 5-FU metabolism are not valuable as markers of response in the present cohort of colon cancer patients. Recently, the results of a clinical trial over the value

1 of some polymorphisms in predicting toxicity in a large group of colon carcinoma patients failed to find
2 any relation between the tested SNPs and toxicity [1]. In that study the value of several SNPs involved in 5-
3 FU metabolism was tested in relation to toxicity. In the same way, we cannot show any value of these SNPs
4 as markers of response to 5-FU in our group of patients.
5

References

1. Braun, M.S., et al., *Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial*. J Clin Oncol, 2009.
2. Longley, D.B., W.L. Allen, and P.G. Johnston, *Drug resistance, predictive markers and pharmacogenomics in colorectal cancer*. Biochim Biophys Acta, 2006. **1766**(2): p. 184-96.
3. Longley, D.B., D.P. Harkin, and P.G. Johnston, *5-fluorouracil: mechanisms of action and clinical strategies*. Nat Rev Cancer, 2003. **3**(5): p. 330-8.
4. Ichikawa, W., et al., *Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen*. Clin Cancer Res, 2006. **12**(13): p. 3928-34.
5. Kawakami, K. and Y. Watanabe, *Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene*. Cancer Res, 2003. **63**: p. 6004-6007.
6. Mandola, M.V., et al., *A novel single nucleotide polymorphism within 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity*. Cancer Res, 2003. **63**: p. 3898-2904.
7. Popat, S., A. Matakidou, and R.S. Houlston, *Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis*. J Clin Oncol, 2004. **22**(3): p. 529-536.
8. Vallböhmer, D., et al., *DPD is a molecular determinant of capecitabine efficacy in colorectal cancer*. Int J Oncol, 2007. **31**(2): p. 413-8.
9. Gosens, M.J., et al., *Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer*. Int J Cancer, 2008. **123**(8): p. 1941-9.
10. Ishikawa, M., T. Miyauchi, and Y. Kashiwagi, *Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy*. BMC Cancer, 2008. **8**: p. 188.
11. Ochiai, T., et al., *Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy*. Int J Cancer, 2006. **118**(12): p. 3084-8.
12. Ochiai, T., et al., *Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy*. J Surg Oncol, 2006. **94**: p. 45-50.
13. Suchi, M., et al., *Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families*. Am J Hum Genet, 1997. **60**(3): p. 525-39.
14. Artinyan, A., et al., *Molecular predictors of lymph node metastasis in colon cancer: increased risk with decreased thymidylate synthase expression*. J Gastroint Surg, 2005. **9**: p. 1216-1221.

- 1 15. Ciaparrone, M., et al., *Predictive role of thymidylate synthase, dihydropyrimidine*
2 *dehydrogenase and thymidine phosphorylase expression in colorectal cancer*
3 *patients receiving adjuvant 5-fluorouracil*. *Oncology*, 2006. **70**: p. 366-377.
- 4 16. Lassmann, S., et al., *Predictive molecular markers for colorectal cancer patients*
5 *with resected liver metastasis and adjuvant chemotherapy*. *Gastroenterology*,
6 2007. **133**: p. 1831-1839.
- 7 17. Liersch, T., et al., *Lymph node status and TS gene expression are prognostic*
8 *markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based*
9 *chemoradiotherapy*. *J Clin Oncol*, 2006. **24**(25): p. 4062-4068.
- 10 18. Metzger, R., et al., *High basal level gene expression of thymidine phosphorylase*
11 *(platelet-derived endothelial cell growth factor) in colorectal tumors is associated*
12 *with nonresponse to 5-fluorouracil*. *Clin Cancer Res*, 1998. **4**: p. 2371-2376.
- 13 19. Yanagisawa, Y., et al., *Modified irinotecan/5-FU/Leucovorin therapy in advanced*
14 *colorectal cancer and predicting therapeutic efficacy by expression of tumor-*
15 *related enzymes*. *Scan J Gastroenterol*, 2007. **42**: p. 477-484.
- 16 20. Farina-Sarasqueta, A., et al., *TS gene polymorphisms are not good markers of*
17 *response to 5-FU therapy in stage III colon cancer patients*. *Cell Oncol*, 2010.
- 18 21. Tokunaga, Y., H. Sasaki, and T. Saito, *Clinical role of orotate*
19 *phosphoribosyltransferase and dihydropyrimidine dehydrogenase in colorectal*
20 *cancer treated with postoperative fluoropyrimidine*. *Surgery*, 2007. **141**: p. 346-
21 353.
- 22 22. Tsuji, T., et al., *Tumor dihydropyrimidine dehydrogenase expression is a useful*
23 *marker in adjuvant therapy with oral fluoropyrimidines after curative resection of*
24 *colorectal cancer*. *Cancer Chemother Pharmacol*, 2004. **54**: p. 531-536.
- 25 23. Westra, J.L., et al., *Predictive value of thymidylate synthase and*
26 *dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly*
27 *treated stage III colon cancer patients*. *Ann Oncol*, 2005. **16**: p. 1646-1653.

Tables and figures

Table 1: Frequencies of the different alleles

SNPs	Frequencies N (%)
OPRT	
GG	44 (75)
GC	15 (25)
CC	0 (0)
TYMP	
GG	25 (42)
AG	29 (48)
AA	6 (10)
TYMS	
2 repeats	10 (17)
2 & 3 repeats	35 (58)
3 repeats	15 (25)
TYMS SNP	
2R/2R	10 (16.7)
2R/3RC	16 (26.7)
2R/3RG	19 (31.7)
3RC/3RC	7 (11.7)
3RG/3RC	4 (6.7)
3RG/3RG	4 (6.7)
DPYD	
AA	37 (67)
AG	14 (26)
GG	4 (7)

Figure 1: Kaplan Meier Curves for PFS according to all genotypes tested; a) TYMP genotypes, b) OPRT, c) DPYD, d) TYMS repeat e) TYMS expression category determined by SNP genotypes (Low expression 2R/2R, 2R/3C, 3C/3C; High expression 2R/3G and 3G/3G)